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11. Introduction: Progress and Challenges 
for (Health) Innovation in China
Beyond the often-celebrated impacts on economic growth, China’s opening up 
since the 1980s has also helped it to contribute more than any other country to 
the successful realization of the Millennium Development Goals. China’s recent 
development has delivered millions out of poverty, and the current reforms to 
its health system have the potential to bring about the most significant single 
national increase in the provision of basic healthcare in the history of the world. 
The achievements are among the embodiment of the current administration’s 
concept of the ‘scientific outlook on development’ (科学发展观), which hopes 
to link socially equitable and environmentally sustainable development goals. 
Premier Wen described the principles behind this concept in an interview in 2008:
The number-one principle is to put people first. The second is 
comprehensive development, the integration of economic development 
with social development, the integration of economic reform with political 
reform, the integration of an opening-up and inclusive approach with 
independent innovation, and the integration of advanced civilization with 
traditional Chinese culture. Thirdly, we need to resolve the disparities - 
rich-poor disparity, regional disparity, and urban-rural disparity - in our 
country’s developmental process. Fourthly, sustainable development: that 
is, to meet the challenges of population, resources, and environmental 
protection faced by a population of 1.3 billion in its modernization process 
(Wen 2008: 363).
The ‘scientific outlook on development’ has been understood as a Chinese 
version of ‘inclusive development’ by other Chinese authors working in the 
innovation studies field (Gu et al. 2010). This paper investigates the ways in 
which innovation studies can contribute to informing solutions to the challenge 
of inclusive development, focussing on the health sector, in which exclusion and 
inequity are particularly severe (Tang, S. et al. 2008).
Alongside its gradual integration into the world economy, China has not only 
accumulated a large stock of Foreign Direct Investment (FDI), delivered 
breathtaking growth over a sustained period and grown to become a leading force 
in global governance (as illustrated by the recent appointment of Chinese nationals 
to a number of top positions in intergovernmental organisations, including the 
World Health Organisation), but is also emerging as a key international player 
in Research and Development (R&D). Gross domestic expenditure on R&D in 
China has increased at an accelerating rate since 1995, and in 2006, it invested 
the third largest national sum in R&D (PPP) in the world after the US and Japan 
(OECD 2008). In 2010, China’s GERD represented 1.75% of GDP (MoST 
2011), and by 2020, the country aims to dedicate 2.5% of GDP to research 
2and development (State Council 2006). At the same time, China’s authorship 
of scientific publications also surged from 4% between 1999 and 2003 to 10% 
between 2004 and 2008 (Royal Society 2011) and now ranks second in the world 
(MoST 2011). In the biotech industry, a typical knowledge-intensive industry, there 
are also signs of fast growth. China has a long history in health biotechnology, 
being the only ‘developing country’ that participated in the human genome project. 
Recent growth in its global share of world publications in various fields related to 
health innovation are illustrated in Table 1 below (Adams et al. 2009).
The question remains, however, whether emerging innovation activities, largely 
led by foreign investment, will translate into longer-term indigenous innovation-
led industrial development of a form consistent with China’s objectives of a fair 
and moderately well-off (shaokang) society. In addition, the surge of innovation in 
China has great significance, not only for the benefit of its own large population, 
but also for sustainability and development in other parts of the world. For 
example, the country exports inexpensive pharmaceuticals around the world, 
and China’s role in providing medical aid and support to sub-Saharan Africa is 
increasing (Ruger and Ng 2010). Have China’s biotechnology advances to date 
had a positive influence on reducing poverty and disparities between rich and 
poor areas?  To what extent might the country’s newfound innovation capabilities 
contribute to solving these widely-recognised national problems and similar 
‘social sustainability’ challenges at a global level? In this paper, we would like to 
make a brief exploration of these questions, drawing on data and case studies 
from China’s biotechnology sector.
1999-2003 2004-2008
Field Count World Share 
(%)
Count World Share 
(%)
Pharmacology 
and toxicology
2,259 3.11 6,614 7.28
Biology and 
biochemistry
6,697 2.66 15,971 5.86
Microbiology 921 1.38 3,863 4.74
Molecular biology 
and genetics
1,642 1.43 6,210 4.49
Immunology 493 0.87 2,114 3.51
Table 1. China’s world share of publications in fields relevant to health innovation 
(1999-2008) (Adams et al. 2009). 
The paper is organized as follows: In Section 2, a research framework for 
biotechnology innovation, sustainability and governance is put forward, 
which focuses on the idea of social sustainability and the global governance 
3of biotechnology innovation. We then focus on the development of China’s 
biotechnology sector and question its economic and institutional sustainability in 
Section 3. In Section 4, we turn to discuss the impact of biotechnology innovation 
on broader notions of social sustainability, focusing on the importance of health 
equity in China and adopting a ‘3D’ approach. Then, in the final section, we try to 
explore the roots of the obstacles which prevent biotechnology innovation from 
contributing more to  social sustainability objectives, and raise questions about 
how the governance of (biotechnology) innovation at national and international 
levels might be reorganized to overcome these obstacles. 
2. Biotechnology, Sustainability and 
3D Innovation Governance
2.1 Characteristics of the Biotechnology Innovation System
Studies of innovation systems at national and regional levels have pointed to 
the roles of specific institutions (and the linkages between them) in fostering the 
development, deployment and diffusion of innovations (Lundvall 1992; Nelson 
1993, Freeman 2002). Similar ideas have been applied to the study of innovation 
systems at the level of sectors (Malerba 2004: 13-17). Biotechnology innovation 
systems possess certain characteristics that distinguish them from those of 
other sectors. This section describes these properties, and then introduces 
the concepts of social sustainability and innovation governance, providing the 
theoretical framework for this paper. The biotechnology sector is marked by 
extended linkages and networks between private entities, including relationships 
between pharmaceutical firms and smaller biotech companies. Research 
partnerships, alliances between private and public institutions and regional 
networks all incorporating network and knowledge links are essential elements 
(Preverzer and Tang 2006; Preverzer 2008). The EU-funded EPOHITE project 
distinguished four categories of actors within biotechnology innovation systems 
in Europe (Lacasa et al. 2004). Within each of these, linkages to other actors - 
both domestic and international – formed an important contributor to innovation 
capabilities in different countries. According to the report, the major players in 
biotech include: 
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Source: Lacasa et al. (2004)   
* denotes international influences  
• The public sector research organizations, including universities and research 
institutions. 
• Biotechnology companies including domestic firms and overseas firms
• Venture capitalists (VCs)
• Government Agencies, including central, provisional and local levels
• Users: including the rich, middle-income and the poor
These interact within the biotechnology innovation system represented in Figure 
1 below. This will act as the analytical framework for subsequent sections of the 
paper.
Figure 1. Research Framework of the Biotech Innovation System (Lacasa et al. 
2004). * denotes international influences 
A second fundamental characteristic of the biotech industry is its close link to 
basic science (McMillan et al. 2000). Scientists at biotech research institutes, 
universities and private companies regularly publish in leading scientific journals 
and file key patents (Murray 2002). Studies of the geography of biotech show 
a tight distribution of innovative small firms around star scientists (Zucker et al. 
1998). Biotechnology start-ups often tend to cluster around research institutions, 
especially universities (Prevezer and Swann 1996).
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A third characteristic specific to biotechnology innovation systems is the sectoral 
ecology (Lehrer and Asakawa 2004). The variety of skills needed to develop 
and commercialize the life sciences includes scientific, clinical, manufacturing, 
legal, financial, regulatory, marketing and distribution capacities. Basic scientific 
research is usually carried out by publicly funded universities and research 
institutions, development activities by large companies, and the search for 
new production techniques by small innovative firms (Henderson et al. 1999). 
There is substantial venture capital involvement and an active stock market for 
technological start-ups (Feldman and Romanelli 2006). Legislative innovations, 
legal expertise, and the rule of law have also played a vital role in enabling the 
growth of the biotechnology sector in leading countries such as the USA and 
Europe (Malinowski 2004). The roles of these actors and components of the 
biotechnology innovation system will be a key focus of the analysis in this paper.
2.2 Sustainability and Governance
The principle of sustainable development was first articulated in Our Common 
Future, the report of the Brundtland Commission (1987). Sustainable development 
can be seen as a process of change in the way that society is organized - 
closely related to how human societies have sought to alter the ways science 
and technology, economic growth and social harmony (as well as environmental 
protection) co-develop (Carter 2007: 207-8). Seen as an outcome, sustainability 
is seen to depend not only on the materials necessary for a good life, but also on 
good social relations and on the relationships between individuals, societies and 
their natural environment (Adger and Jordan 2009). 
In 1987, Brundtland’s definition of sustainable development as ‘development 
that meets the needs of the present without compromising the ability of future 
generations to meet their own needs’ (WCED 1987: 43), focused on two further 
concepts: ‘the concept of needs, in particular the needs of the world’s poor, to 
whom priority should be given’, and ‘the idea of limitations imposed by the state 
of technology on social organization and the environment’s ability to meet present 
needs and cultivate further development’ (WCED 1987:43). Whilst it did not 
separate out ‘social sustainability’, this term has been used since as shorthand for 
the two ‘pillars’ of sustainable development (other than environmental protection) 
highlighted at the 2005 World Summit (United Nations 2005). For the purposes 
of this paper, social sustainability relates to the goals of equity, cultural integrity 
and the preservation or provision of social support structures, including through 
just political systems that support human capabilities for social and economic 
development in the long-term. 
6Whilst many have tried to reduce (social) sustainability to simple indicators or 
metrics, this paper, does not see sustainability as an objectively determinate 
quantity, but as a concept that maintains ‘the creative tension between a few 
core principles and openness to re-interpretation and adaptation to different 
technological, social and ecological contexts’ (Kates et al. 2005). Sustainability is 
therefore an outcome of universal appeal but needs to be carefully thought about 
and deliberated upon (Adger and Jordan 2009). 
Governance refers to those social activities which seek to ‘guide, steer, control 
or manage’ these activities (Kooiman 2003). Western literature describes the 
patterns that emerge from the governing activities of diverse actors in what is 
deemed acceptable norms of behaviour and divergent institutional forms (Ostrom 
2005), the contributions of government, non-state actors such as businesses and 
non-governmental organizations (NGOs) involved in societal steering (Lemos and 
Agrawal 2006), aspects of governance at different spatial scales—international, 
national and sub-national (Cash et al. 2006). As such, governance for sustainability 
and development should be an interactive and reflexive process of debate and 
dialogue, which is equipped to deal with dilemma, disputable struggles and the 
risk of serious conflicts (Meadowcroft et al. 2005: 6-8). At the international level, 
scholars have focussed on international agreements, multi-lateral organizations 
and private organizations such MNEs as well as the UN system (Stiglitz 2004 
2006; Michie 2003; Levy and Newell 2004; Glasbergen et al. 2007; Xue 2007; 
Adger and Jordan 2009)
2.3 Globalization and the Governance of STI for Sustainability
Globalization is characterized by the systematic reduction in the barriers to the 
cross-border flow of factors (labour, capital), products, technology, knowledge, 
information, as well as belief systems, ideas and values. Globalization arises 
alongside the growing complexity and reach of scientific and technological 
advances, and leads individuals, institutions and nations to widen their activities 
across national boundaries (Kaplinsky 2005). The process of globalization is 
affecting the production, distribution and transfer of technology (Bartlett and 
Ghoshal 1989; Dunning 1992; Ely and Scoones 2009). Technological globalization 
can be divided into three categories: the global exploitation of technology, global 
technological collaboration, and global generation of technology (Archibugi and 
Michie 1997), and the strategies developed by both government and business 
institutions to generate knowledge and technologies are extending beyond 
single country borders (Archibugi and Michie 1995). However, the majority 
of the world’s new technologies are still primarily developed and utilized in 
industrialized countries. Mobilizing this knowledge to meet the agriculture, health, 
7communication and environmental needs of developing countries will continue to 
be one of the most important issues in international relations (Juma et al. 2001). 
Globalization thus represents a major challenge to governance. Public institutions 
are traditionally held accountable to their nation-based citizens, while business 
firms are in theory accountable to stateless shareholders. Alongside continuing 
globalization, changes have occurred in social, cultural and political life, impacting 
local communities including nation-states, and lowering ties of national identity, 
citizenship and political sovereignty (Robertson 2003). 
In the domain of health biotechnology, issues of ‘social sustainability’ have 
received a great deal of scholarly attention as new, emerging technologies raise 
different debates and political responses in various jurisdictions across the world. 
Without an overt focus on ‘sustainability’, Gottweis (1998) and Jasanoff (2005) 
have compared the political and regulatory debates around health and agricultural 
biotechnology in the USA and Europe. On the other hand, Torgersen and Seifert 
(1997) have focused directly on ‘social sustainability’ debates in relation to genetic 
technologies and the concept of ‘sozialverträglichkeit’ (social unsustainability or 
unbalanced burden on society or social groups) in Austria’s Genetic Engineering 
Act. 
At international levels, scholars have studied the role of existing and new 
biotechnologies in promoting international development (Daar et al. 2003), 
analysed innovation approaches aimed at groups not served by market 
mechanisms (Chataway and Smith 2006), and made arguments for further global 
health research on the basis of human rights (Pogge 2005). In the general area of 
science, technology and innovation, the STEPS Centre’s New Manifesto (STEPS 
Centre 2010) has advocated institutional approaches to ensuring that science 
and technology contribute to social (and other forms of) sustainability through 
increasing transparency and accountability in STI funding, enabling broader 
participation in decision-making around support for research and development 
and for wider innovation policies.
Social sustainability concerns are at least as pressing to the Chinese Communist 
Party as environmental impacts of the current form of growth. Some international 
commentators, like Will Hutton, have argued that China’s authoritarian approach 
to capitalism risks social unrest (Hutton 2011), echoing calls for significant 
constitutional reform from senior academics within China (Yu 2007a: 3). There are 
signals to indicate that these pleas are being heeded, at least in that the central 
committee intends the policy making culture to move to a more consultative 
mode (in addition to expanding the formal role of the Chinese Peoples’ Political 
Consultative Conference). However, in the field of science and technology, 
fundamental deficits in transparency (for example around R&D funding decisions) 
and problems of public accountability remain. Although authors such as Sleeboom-
Faulkner (2009; 2010) have discussed the ethical debates that have been 
witnessed in China around the governance of new medical technologies such as 
biobanks and stem-cell lines, and other scholars (e.g. Tang, S. et al. 2008) have 
8discussed the challenges of health equity, the link between the country’s health 
biotech innovation system and concerns of social sustainability have so far been 
relatively neglected in the scholarly literature. Even less studied are the policy 
processes and governance arrangements that relate to these areas.
From the 1990s ‘global governance’ emerged as the key term for international 
reform as well as a conceptual tool in political research such as environmental 
standard-setting, health and the reform of international institutions (Rosenau 
1997; Held and McGrew 2002; Stiglitz 2003; Cogburn 2003; Dhar and Gopakumar 
2006; Xue 2007). Institutionalist perspectives on international governance suggest 
that international institutions can deeply affect how states behave towards each 
other and stress the importance of international regimes - sets of principles, 
norms, rules and decision-making procedures around which actor expectations 
converge in a given area of international relations (Krasner 1983; Koenig-
Archibugi 2002). Non-state actors, especially NGOs, business entities, and the 
staff of intergovernmental organizations (IGOs) can work together towards the 
resolution of public problems (Rosenau 2000). Regulations on global business 
follow industry self-regulatory practice more than the reverse, and multilateral 
IGOs can exercise influence by forging alliances, sponsoring research, mobilizing 
technical expertise, raising public awareness and playing a leadership role in 
negotiation (Archibugi and Pietrobelli 2003). 
A typical example in the global governance of the science and technology 
domain is the World Trade Organization Agreement on Trade Related Aspects 
of Intellectual Property (WTO TRIPs), whose rules increasingly determine the 
health, agriculture, environmental, food safety rules of communities (Guzman 
2004; Guzman and Simmons 2005) and to which we return later in this paper. 
The STEPS Centre’s ‘New Manifesto’ outlines a number of ‘areas for action’ for 
the global governance of innovation for sustainability, social justice and equitable 
development, focusing on what it calls a ‘3D’ agenda. This agenda argues 
that current political debates around science, technology and innovation pay 
insufficient attention to the following (Stirling 2009):
- Direction – the direction in which science, technology and innovation are 
moving, rather than the scale (e.g. volumes of funding support) or the rate (e.g. 
publications or patents per year) of change;
- Distribution – the more equitable distribution of the costs, benefits and 
risks associated with innovations; and
- Diversity – maintaining or enhancing diversity in STI approaches 
to sustainability and development challenges, in order to avoid lock-in to 
unsustainable pathways, cater for seemingly irreconcilable perspectives and 
priorities and build resilience in the face of uncertainty.
9In the remainder of this paper, we will draw upon the theoretical ideas outlined 
above, especially the characteristics of biotechnology innovation systems and 
the 3D agenda for innovation governance, in our analysis of China’s health 
biotechnology sector.
3. China’s Biotechnology Innovation System: 
Achievements and Challenges
Before discussing the social sustainability impacts of China’s health biotechnology 
innovation system, we review some of the achievements that have been reached 
and challenges faced over the past thirty years in which it has emerged. 
3.1 Achievements of China’s Health 
Biotechnology Innovation System
China has experienced rapid growth in the biotech industry since 1996 when the 
Chinese government announced its policy of prosperity for the country through 
scientific and educational advances (Fang and Mu 2008). China’s investment 
in research and development in the agricultural field has raised the question of 
whether it can be described as a ‘biotech developmental state’ (Keeley 2003), 
drawing on earlier analyses of East Asian industrialisation (White 1988). Extending 
their analysis to health and environmental sectors, Zhang et al. (2010) have also 
used the ‘developmental state’ model, contrasting it with public-private partnership 
and entrepreneurial models (drawing from Cook and Kwon’s 2007 typology). 
They argue that the country has adopted a hybrid model, providing large amounts 
of funding to support public sector R&D, fostering cooperation between academia 
and enterprises, and gradually liberalising markets to generate internationally 
competitive biotechnology firms. The story of the evolution of China’s (health) 
biotechnology innovation system is re-told here. 
The modern Chinese biotechnology industry came into existence around the 
1970s. From the beginning stage until the end of the 1980s, it was mainly based 
on research activities in the public institutions, and some biopharmaceutical firms 
were founded as spin-offs of universities and public research institutions (MoST 
2008). From 1981 to 1985, government funding for biological research increased 
more than 25-fold, and new mechanisms were introduced to allocate resources 
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by competitive peer-reviewed grants. During the seventh 5-Year Plan (1986-
1990), the level and scope of biotech funding also increased rapidly. The State 
Council launched the ‘The National High Technology Research and Development 
Program of China’ (referred to as the ‘863 Plan’) in March 1986 (Fang and Mu 
2008). A small number of academics established firms in this phase, contributing 
to linkages between research and industry. 
From the mid-1990s China’s biotech industry policy shifted towards an 
entrepreneurial system. The policies included support for start-ups, drawing 
‘returnees’ back from abroad (Chun Hui Programme of 1996) to create new 
ventures, stimulating science parks and industrial clusters, and establishing a 
venture capital industry. As the following section suggests, these processes are 
still in progress. 
Research was driven by National Basic Science (973) and other programmes. 
Instead of merely transplanting Western science, China began to make use of 
modern biotechnology to solve national problems and to promote indigenous 
innovation (Chen et al. 2011). International biotech firms, attracted by China’s 
1.3 billion consumer-markets and its low labour costs, rushed into China for 
manufacturing and acquired local knowledge, legislated patents, and set up R&D 
centres (Liu and An 2008).
Since China joined the World Trade Organization (WTO) in 2001, it has integrated 
more completely into the global economy. Accession to the WTO binds China 
to various principles, such as improved transparency and the strengthening of 
commercial legal procedures. China’s WTO commitments include the tightening 
of intellectual property protection, tariff concessions, and market access of non-
Chinese service suppliers engaging in the distribution of biotech pharmaceuticals 
and other biotech products (Grace 2004). At this stage, biotechnology research 
and industry development in China entered a new era with the creation of a 
national biotechnology leadership group. Funding for biotechnology research 
came from two sources: government and enterprises. From 2001 to 2005, the 
Chinese government spent a total of about 10 billion CNY (approx 1.2 billion USD) 
on biotechnology research mainly through the Ministry of Science and Technology 
(MoST), National Science Foundation of China (NSFC), China Academy of 
Science (CAS) and relevant local governments (NDRC 2008). Among these, 
MoST administrated more than half of the government funding (Lakhan 2006). 
The achievements of China’s biotech innovation system can be partially illustrated 
below in Table 2, which gives indicators of biotech innovation, including the number 
of SCI papers published, global patents and the growth rate of biotech patents 
in modern biotechnology. China’s number of global (PCT) patents accumulated 
from 1995-2006 is still tiny at only 1.7% of the world total, compared with USA 
(43.3%), Japan (14.1%), Germany (9.6%). But the annual growth rate of China’s 
global biotech patents is substantial (49.3%), much higher than leading countries, 
and even higher than other emergent countries such as India (30.4%), Russia 
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(19.6%) (NDRC 2008). 
Country Number of SCI 
Papers in Biotech 
Fields
Number of Global 
Patents in Biotech 
Fields
Annual Growth Rate 
of Biotech Patents 
from 1995-2006
Number Ranking Percentage 
(%)
Ranking Growth 
Rate (%)
Ranking
USA 37,822 1 43.3 1 1.5 20
UK 7,565 2 5.3 4 2.8 19
Germany 7,497 3 9.6 3 10.1 6
Japan 6,298 4 14.1 2 8.2 9
France 5,172 5 3.6 5 6.3 14
Canada 4,194 6 2.7 6 5.2 16
China 1,481 13 1.7 9 49.3 1
Russia 1,019 17 0.2 19 19.6 4
India 789 20 0.8 16 30.4 2
Table  2. Publication and patenting of leading countries in the biotech industry, 
1995-2006
Source: 
(1) SCI paper data source: China Ministry of Science and Technology (2009)
(2) Patent data source is from OECD, PCT database, from: http://www.oecd.org/
document/41/0,3746,en_2649_34451_40813225_1_1_1_1,00.html  
(3) The data are accumulated numbers from 1995 to 2006
The number of biotech firms has also been increasing, thanks in part to the Chinese 
government’s encouragement of entrepreneurship and attraction of Chinese 
returnees into the nascent biotech industry since 2002. In 2003, there were around 
500 biotech firms in China according to an Association of German Biotechnology 
Company report (Tang, 2004, p.24). According to an OECD report, there are 158 
biotech firms, 31 R&D institutions and 22 higher education in Shanghai alone 
(OECD 2006). However, the true size of the Chinese biotech industry (especially 
innovation-based biotech firms) is difficult to gauge due to two reasons: firstly, 
many companies label themselves as ‘biotech firms’ or are labeled as such since 
they are located in the high-tech park, but actually they are only involved in the 
processing of chemical components for pharmaceutical companies; secondly, 
most industry reports do not differentiate between ‘pharmaceutical’ and ‘biotech’ 
industries (Sternberg and Müller 2005). Numbers are further complicated by the 
emergence of the contract research organisation (CRO) phenomenon in the 
global biotech and pharmaceutical industry. With the increasing specialization 
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and modularity of R&D, transnational biotech pharmaceutical firms have begun to 
outsource their R&D or clinical experimental work to these private organizations, 
which provide full-service pre-clinical testing and clinical trials. Proximity to these 
partners has been highlighted as one of the reasons for European MNEs to move 
R&D offshore (Ujjual et al. 2011). China attracted negligible outsourcing activities 
of this kind before 2000, but in 2001 it took 0.4% of the global proportion of clinical 
trials, and in 2006 it reached nearly 1% (NDRC 2008). 
China’s biotechnology industry has maintained relatively steady growth in outputs 
since 1995. The total value of outputs of the biotech sector increased rapidly and 
reached around 60 billion RMB in 2007 (nearly 8 billion USD) after expanding 
at around 19% from 2002 to 2007 per year based on the national statistics 
data (NDRC 2008). Value added and profits followed a similar growth pattern, 
as illustrated in Figure 2 below. Industry analysts have argued that the market 
for ‘genetic biotechnology products’ is due to increase enormously because of 
growing demand for medicine, consumer preference for lower costs, forthcoming 
patent expiries and regulatory reforms to promote bio-generics (Festel 2007).
Figure 2. Total Value of Outputs, Value Added and Profits of Biotechnology 
Companies in China (1995-2007), source: China Statistics Yearbook on High 
Technology Industry (2001-2008)
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3.2. The Challenges to (Sustained) 
Innovation in Biotechnology 
China has been building capabilities for ‘indigenous innovation’ in biotechnology 
and other sectors, however there remain potential stumbling blocks to sustaining 
this process. On the basis of the system of innovation framework outlined above, 
these include challenges in the domain of creating truly innovative firms and 
providing ongoing finance to the industry. In addition, we briefly discuss issues 
relating to the demand side and social acceptability.
The history of China’s biotechnology/ pharmaceutical industry has been based 
around the production of generic medicines and to a large extent this continues. 
Liberalisation has led the number of firms in pharmaceutical production to increase 
substantially, although only a small minority of the firms produce anything other 
than copies or similars. The biotech market segment (which includes genetically 
engineered drugs, vaccines, antibodies and blood products) represents only 
7.4% of China’s entire pharmaceutical industry, for which there are an estimated 
130 million daily consumers. Total revenues of the entire Chinese biotech industry 
amounted to 5.62 USD billion in 2006, which is only 10% of US biotech industry 
revenues (53.5 USD billion) in the same period (NDRC 2008).  
Although China’s R&D capabilities are now well-developed, challenges still 
remain in terms of converting knowledge to value through the activities of 
innovative firms. China needs to generate a much greater intensity and diversity 
of indigenous innovation. Discussing ‘developing countries’ in general, Bell 
(2009) points to the importance of complementarities between local innovation 
capabilities (especially design and engineering-focused capabilities) and both 
local R&D and technology imports. From the history of China’s biotech industry (as 
discussed above), it is clear that public policies have focussed on fostering R&D 
capabilities organized in central and usually public institutes like national centres 
and leading universities, with less attention given to strengthening the creation 
and use of complementary capabilities in production enterprises. In addition 
there has been a heavy concentration within firms on acquiring technology/ 
knowledge (or human resources in the form of overseas students returning to 
China) via imports from advanced economies, and less focus on creating and 
using their own complementary innovation capabilities. The government’s ‘Torch’ 
programme was initiated in 1989 to promote high-tech development, but was 
restructured as part of  the Medium-Long Term Plan by integrating the functions 
of the government’s innovation fund for technology-based SMEs, and the China 
Technology Market Management and Promotion Centre. The new Torch Centre 
(Technology Transfer Market Administration Centre) now plays the role of making 
policies and providing ‘angel investment’ to firms, taking forward research from 
the country’s mega-research projects and 863 programme, through the ‘valley of 
death’ (the period between R&D and deployment where funding is traditionally 
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very difficult to obtain) and towards commercialisation.
Patenting, as mentioned earlier, has been much slower to develop than the 
knowledge base itself, and, notwithstanding the limitations of patent statistics 
(Li 2008), this may be indicative of a time-lag in ‘new to country’ and ‘new to 
world’ innovations. Part of the reason for this lag in innovative performance is the 
poor linkages between firms and the research institutions that have excelled over 
past years. The country is trying to overcome this by promoting entrepreneurship 
amongst academics, with some successful results. In addition, various provincial 
governments have attempted to build ‘high-tech clusters’ by encouraging the 
geographical proximity of research institutions and firms in the same sector, 
however with limited success. Zhang et al. (2010) attribute the weakness of these 
initiatives to the state-sponsored R&D model, which promotes vertical rather than 
horizontal linkages.
For the Chinese health biotechnology innovation system to successfully deliver 
products and services contributing to social development, the availability of 
finance (including from private venture capital, industrial development agencies 
and stock markets) is vital. From a global perspective, whilst the ‘knowledge/skills’ 
component of the system appears well-developed, the Chinese venture capital 
investment in biotech companies is quite small. In China, venture capital invested 
in life sciences was only 315.8 million USD in 2007. This is less than 6% of that 
invested in USA in the same year and compares to a total of 8,064 million USD 
PPP venture capital investments in the life sciences for all 25 reporting OECD 
countries in 2007 (OECD 2009). In terms of products on the market, China’s 
offerings are also dwarfed by activities in the larger markets. Until recently, the 
Chinese biotechnology industry’s total product sales only accounted for less than 
half those of the major biotechnology firm Amgen in the United States (Zhang et 
al. 2010). 
The financial strategies of China biotech companies are different from those of 
western biotech counterparts (Chen et al. 2011). The evolution of the US biotech 
trajectory has shown that venture capital plays a key role in financing biotech 
(Etzkowitz and Leydesdorff 2000). However, the stock market in China is relatively 
young and focussed on low-risk investments, so in general venture capital (VC) is 
difficult to come by. Most Chinese biotech firms receive funds from state-owned 
enterprises or government at different levels, ranging from central (e.g. the 
Ministry of Science and Technology often provides some initial funds through its 
863 and 973 programmes) to provincial and local, or indeed from entrepreneurs 
themselves. Di Masi et al. (2003) estimated that the cost of developing a new 
drug and bringing it to market in the USA would average approximately USD 800 
million over 12 years, necessitating huge long-term investment that government 
is incapable of delivering.
Looking beyond biotechnology, the pattern of total venture capital sourcing in 
China is illustrated below. Financial sources from government are limited and 
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cannot ensure sustained investment over the longer-term (beyond the early R&D 
stage through to development and testing of drugs). Moreover, the government 
officials usually lack professional experience in VC activities, limiting their 
understanding of growth in the biotech industry and their ability to invest wisely. 
Private venture capital may even be afraid of government over-intervention in the 
future development of biotech companies. 
Because China’s private venture capital sector is still at an embryonic stage, 
Chinese biotech companies often adopt a ‘hybrid business model’, which means 
that these companies survive on selling biogenerics in order to develop profits 
that can be invested in R&D. This kind of hybrid business model can dilute 
entrepreneurial and financial resources, and is not necessarily favorable to 
overseas or domestic venture capital.
Year 2003 2004 2005 2006 2007 2008 2009
Domestic Financial 
Resources (%) of which:
95 n.a. 66.1 56.3 44.4 50.6 53.9
Government (%) 26.3 n.a. 31.9 33.6 24.1 25.2 21.8
Financial Institutions 
(%)
6.3 n.a. 14.8 13.0 7.0 10.7 9.5
Firms (%) 52.6 n.a. 46.4 44.9 53.5 39.7 44.7
Individuals (%) 10.5 n.a. 3.0 5.7 10.5 19.3 23.5
Other (%) 5.3 n.a. 3.8 2.7 4.0 5.1 0.9
Overseas Capital (%) 5 n.a. 33.9 43.7 55.6 49.4 46.1
Table 3. Financial Sources of Venture Capital in China 2003-2009. Source: 
Yearbook of China’s Venture Capital Investment 2010 (Cheng 2010). 
Table 3 illustrates that overseas sources of venture capital played an important 
role in China from 2005 and grew steadily before falling again around the time 
of the downturn in Western economies. Government’s share of domestic venture 
capital began to fall after 2005, with venture capital from individuals showing a 
steady increase. Although we have no specific data on VC in the biotech industry, 
we have no reason to believe that the general trends seen throughout the VC 
sector are not similar to those seen within biotech. We will later discuss the 
possible impacts of these trends with respect to the directions of innovation. Firms 
and financial institutions have increased their share since 2005, but a strong trend 
is not visible over the period for which data are available, suggesting that up until 
that point the venture capital industry in China was still in an emergent phase, 
unable to provide the kinds of support that allowed the growth of the sector in 
leading countries. Whilst VC from individual sources has increased steadily, due 
to the short-history of the biotech industry in China, domestic venture capital is 
generally inexperienced and only able to provide funds, in the absence of the 
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managerial support offered by angel investors and VC in more developed markets.
The size of China provides great potential for domestic firms, but the market is yet 
to be exploited. China accounts for 20% of the world’s population but only 1.5% of 
the global drug market (Griesar 2011). China’s changing health-care environment 
is designed to extend basic health insurance to a larger portion of the population 
and give individuals greater access to products and services. The creation of 
wealth (and generation of purchasing power) in rural areas is recognized as part 
of a broader need - acknowledged internationally as well as at home – for China 
to shift growth towards a model based on domestic consumption rather than 
inward investment and export.
One barrier to demand for the biotech products in China is the weak health system 
across the entire country. According to the Chinese Ministry of Health, there are 
only 1.5 doctors per 1,000 people (Ministry of Health 2007). The coverage of 
medical insurance has decreased from 90% in the early 1980s to less than 10% 
in rural areas, making it difficult for patients to afford cheap, generic drugs, let-
alone biotech products, which have a higher price due to patent protection for 
pharmaceuticals – a relatively recent change in China’s health system (Liu 2004). 
Until the early 1990s there was no patent protection for drugs and domestic 
pharmaceutical companies could legally copy drugs developed and patented in 
other countries. In 1993 China amended its patent law, added pharmaceuticals to 
the list of patentable subjects and passed another law that gave foreign companies 
seven and a half years of marketing exclusivity for pharmaceuticals that had been 
patented abroad over the previous six years, but had not yet been marketed in 
China (Van Zwanenberg et al. 2011). Protection of this kind has raised the price 
of biotech drugs for Chinese patients. Recent developments in the patent system 
are discussed in the final section of this paper.
Alongside these challenges related to the unaffordable price of biotech drugs 
for China’s masses, China’s domestically-produced products suffer from low 
levels of trust amongst consumers, who view overseas medicines as safer and of 
higher quality. The current regulatory framework for pharmaceuticals in China is a 
product of a series of reforms dating from the late 1990s and early 2000s, driven 
largely by accession to the WTO and by a desire for further global integration. 
A series of counterfeit drug scandals through the 1980s and 1990s (Dong et al. 
1999) as well a number of scandals in recent years relating to cases of bribery 
or drug contamination (Jia 2008) have led to high profile responses. The former 
director of the State Food and Drug Administration was executed (Nature 2007) 
and in February 2007, top officials ordered an investigation into the functioning of 
the SFDA, including a review of over 170,000 production licenses issued by the 
agency over the past decade, particularly those issued between 1999 and 2002 
(Barboza 2007). Concern within export markets has been great, and has led to 
the USA establishing offices of the Food and Drug Administration in China itself 
(Jacobs and McDonald 2008). Regulatory capacity and improved governance 
(including increased accountability and strengthening of the rule of law) are - 
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alongside the diversification of sources of finance and generation of a strong, 
domestic market – key ingredients in building an innovation system that leads to 
sustained benefits.
4. Addressing Social Sustainability Goals in China’s 
Dynamic Health Biotechnology Innovation System
In this Section we turn to discuss social sustainability issues related to China’s 
health biotechnology innovation system, focusing on the role of poverty reduction 
and health equity in China. We use the 3D agenda from the STEPS Centre’s 
New Manifesto (described in section 2) – a focus on direction, distribution and 
diversity - to consider the social sustainability, impacts and implications of China’s 
current health biotechnology and innovation system. This discussion focuses 
on the various components of systems of innovation as outlined in section 2 – 
knowledge/skills, industry/supply,  finance/industrial development and demand/ 
social acceptability.
4.1 Direction – Biotech innovation for poverty alleviation
The first ‘D’ highlighted in the New Manifesto is that of direction – the direction in 
which science, technology and innovation are moving, rather than the scale (e.g. 
volumes of funding support) or the rate (e.g. publications or patents per year) of 
change. Taking the social sustainability focus adopted in this paper, the key issue 
here is whether the technologies that are emerging from China’s biotechnology 
innovation system are directed at the alleviation of poverty in the country and the 
reduction of inequalities so prominent in political discourse.
The rapid progress in poverty alleviation in the two decades following opening-
up and reform was uneven over time and across provinces (Ravallion and Chen 
2007). Since that time, the GINI index of the country as a whole (measuring the 
degree of inequality in income distribution) has fluctuated, but the overall trend 
shows an increase of around 7% per decade, and the index is expected to reach 
50% (implying high inequality) by around 2015 (Ferreira and Ravallion 2008). 
Disparities in health exist between urban and rural areas, between the costal and 
western regions, and between different households. Wealth has been shown to 
be a strong predictor of health-system coverage in China, and the inequalities in 
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GDP link closely to the availability of health services in different provinces (Liu et 
al. 2008). Box 1 provides more details of health equity issues in China.
Box 1. Equity issues in China’s dynamic healthcare system
At the outset of the reform period in 1979, the Chinese government eliminated free 
primary healthcare (which had often been provided, although imperfectly, through 
the communes), leading most to purchase their own health insurance (unaffordable 
for many). Some have argued that an established right to social assistance could 
not have been so easily—and so swiftly—dropped in a functioning democratic 
society (Sen 2011). Official figures suggest that the life expectancy of developed 
regions such as Shanghai in 2000 was around 77 years, but 10 years lower in the 
poorest provinces (State Statistics Bureau 2006). Indicators for children’s health 
also show substantial disparities. Rural infant mortality rates in poor areas are 
123 versus 26 per 1000 livebirths in the wealthiest regions (Tang, J. et al. 2008). 
These inequalities have risen to become a major political issue in China. 
The Ministry of Health issued a new policy in 2008 stating that ‘Health is the 
cornerstone of comprehensive human development…assurance of health equity 
is now regarded as the key parameter for the social justice and fairness in the 
country. ...Accessibility of basic medical and health care services is a basic right 
of the people’ (Tang, S. et al. 2008). In response to the spiralling cost of healthcare 
in the wake of market reforms, insurance-based support, or direct support for 
the poorest patients, has emerged. In the rural Chinese context the primary 
insurance scheme for rural residents is the New Cooperative Medical Scheme 
(NCMS) administered by the Bureau of Health. The NCMS was launched in 2002, 
with combined financing from both government and individuals, and provides a 
fixed annual sum that families can draw upon to pay for healthcare at village and 
township healthcare facilities. Any remaining costs are paid for out of pocket, 
however research has suggested that the scheme has not reduced out-of-pocket 
expenses, and has pointed to remaining problems with the NCMS, especially for 
the poorest or chronically ill families (which show lower enrolment) (Wagstaff et 
al. 2007). However, reforms are continuing, with the NCMS and a parallel urban 
insurance scheme aiming to achieve universal coverage by 2020 (Dong 2008). 
Directions of health innovation in the West, and more generally in liberalized 
economies, tend to suffer from the 90/10 gap – ‘where 90% of all medical research 
is targeted at problems affecting only 10% of the world’s population’ (Chataway 
and Smith 2006). Innovation directions are thus profit-driven, largely focusing on 
the needs of wealthier markets and treatment (of diseases of consumption) rather 
than prevention. It is worth evaluating whether the experience of China since 
reform and opening up suggests alternative directions of research and innovation 
that might be better-equipped to respond to the needs of China’s enormous rural 
(and urban poor) populations, who continue to suffer from high levels of infectious 
disease, among other complaints. 
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In discussing directions within the context of China’s heavy investment in research, 
it is worth understanding how the state has come to set the R&D priorities for 
biotechnology in China. Government and scientists have dominant roles in the 
decision-making, with the State Council setting overall priorities, the Ministry 
of Science and Technology (MoST) (through various research programmes), 
National Science Foundation of China (NSFC) and Chinese Academy of Sciences 
(CAS) setting programmatic themes for research and selecting projects for funding 
support. The approach of priority-setting in China thus follows what appears to be 
a top-down, directive format, as illustrated in Figure 3 below (Zhang et al. 2010). 
Yet, at the same time, the Chinese government has reportedly made some efforts 
to encourage public engagement in science and technology, including in policy-
making. These include suggestions through the internet on how the country should 
rebuild its science and technology by 2020 (Jing 2003) and similar consultations 
on the reform of the health system (Van Zwanenberg et al. 2011). 
Figure 3. Biotechnology and development management system in China adapted 
from Zhang et al. 2010, based on data from the China National Centre for 
Biotechnology Development (see http://www.cncbd.org.cn) and interview with 
MOST official, 25/8/2011. 
Note: within China’s national biotechnology investment system, the State Council 
has overall responsibility for the distribution of funds. The Ministry of Science 
and Technology (MOST) plays the dominant role in guiding research priorities 
through supporting national programs including the 973 and 863 infrastructure 
programmes and Special Fund for SMEs. In some national programs (e.g. the 
Mega Science and Technology Program and Key Technologies R&D Program), 
MOST works as the dominant ministry alongside Ministry of Health (MOH), State 
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Strategic area Details 
Drug target discovery Functional characteristics of key and disease-related genes: 
drug target screening and validation 
Animal and plant models 
and drug design 
Analysis and integration of bio-information drug design and 
metabolism; computer-assisted designs, syntheses, and 
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Food and Drug Adiministration (SFDA), China Academy of Sciences (CAS). The 
Chinese Academy of Sciences (CAS), Ministry of Education (MOE) and Ministry 
of Human Resource and Social Security (MOHRSS) work together with MOST 
to support the Knowledge Innovation program and to cultivate talents. The 
National Development and Reform Commission (NDRC) plays an important role 
in enhancing the commercialization of research within the biotechnology industry 
through its support of SMEs and enterprise systems at different levels.
The government itself has dedicated significant resources to research into health 
challenges faced by the poorer sections of the country’s population. The Guidelines 
on National Medium- and Long-term Program for S&T Development (2006–2020) 
include drug innovation and control of major emerging infectious diseases within 
a broader portfolio (State Council 2006).  Biotechnology is identified as one of 
eight frontier technologies identified in the plan, and five strategic areas within 
it are illustrated in the table 4 below (Yu 2007b, p. 136, as cited in Zhang et al. 
2010).
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Strategic area Details
Drug target discovery Functional characteristics of key and 
disease-related genes: drug target 
screening and validation
Animal and plant models and drug 
design
Analysis and integration of bio-
information drug design and 
metabolism; computer-assisted 
designs, syntheses, and screening 
of compound libraries based on 
combinatory chemistry
Gene manipulation and protein 
engineering
Chromosome structure and site-
directed integration; design and 
manipulation of protein-coding genes; 
polypeptide chain modification; 
structure solving; scaled protein 
purification
Stem cell-based human tissue 
engineering
Therapeutic cloning, directional 
differentiation; in vitro construction 
of structural organs and production; 
construction and damage repair of 
complex organs with multiple cell 
types
New generational industrial 
biotechnology
Scaled screening of functional 
microbes; modification of bio-
catalysts and industrial production; 
bio-conversion media and systems for 
industrial operation
Table 4. Strategic areas of biotechnology specified by the Medium- and Long-
term Science and Technology Development Plan (compiled from Yu 2007b, taken 
from Zhang et al. 2010)
Prevention and control of HIV/AIDS which together affected nearly a million 
Chinese in 2007 (Zhang et al. 2008), viral hepatitis, which afflicts 20-30 million 
patients in China (Zhang et al. 2010) and other major infectious diseases are 
a key priority for the government (Wang et al. 2008). As such, their inclusion in 
two of the ‘Megaprojects’ emerging from the Medium to Long-term Science and 
Technology Development Plan (Cyranoski 2008) was no great surprise (even if 
the process of eliciting proposals was rushed). The key question is whether these 
investments in research will enable the required directions of innovation in firms 
across the country – one which, again, requires a systemic view.
Linkages between research institutions and firms in China have often been 
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described as weak, creating difficulties for knowledge generated in universities 
or academies to be commercialized (Prezever 2008). The government has 
implemented a number of reforms to try to overcome these obstacles, including 
incentivizing entrepreneurial activities within research institutions through 
enabling them to patent their inventions (Liu and An 2008). However, aside from 
the funding offered under the 863 programme, the government offers little support 
for taking products to the market, and pro-poor research struggles to generate 
interest from the private sector (hampering commercialization). At the same time, 
linkages between firms are limited as well. Interactions between small ‘dedicated 
biotechnology firms’ and large (pharmaceutical) firms have been shown to be 
key to the emergence of a mature biotechnology sector in other country contexts 
(Kenney 1986; Saviotti 1998). Currently, China is devoid of large pharmaceutical 
firms with the finance and focus necessary to purchase or forge strategic alliances 
with small biotech start-ups, leading to a continued dominance of innovation 
directions set by multinational firms. 
The trends outlined in the section above on ‘challenges’ show that VC investment 
in China has begun to move away from that provided by government towards 
the private sector. Without a mandate to serve equity objectives, it appears more 
likely that this sustained funding will contribute to a 90/10 gap similar to that seen 
in other parts of the world. As outlined above, much of China’s biotechnology 
industry exists in the form of contract research organisations. By definition, it is 
unlikely that the priority focus of these organisations relates to locally-determined 
health challenges, and more likely that their efforts have been dedicated to 
innovation serving overseas markets (in what has been described as ‘internal 
brain drain’ - Singer et al. 1970) or, if they are contracted by large domestic firms, 
wealthy markets within China. In a study of MNEs carrying out R&D in China, 
Ujjual et al. (2011) found that some of them were using these centres to develop 
products specifically for the Chinese market, however by-and-large for diseases 
of the wealthy. 
Domestic Chinese firms may play a more significant role in innovating for poorer 
markets in China. The Chinese-educated entrepreneurs and returnees who often 
lead these firms illustrate that ‘brain drain’ is not the whole story. It is estimated 
that over 1.3 million Chinese students have gone abroad to study since 1978, 
over 30% of which have been in the field of biotechnology or related areas 
(MoE 2010), suggesting that this ‘brain circulation’ may have a continued role 
to play in the longer term. Returnees (especially from USA and EU) have played 
a significant role in contributing to the development of modern biotechnology 
innovation in China since the year 2000. There has been a favorable environment 
for returnees to set up their own business in returnee parks (high-tech zones set 
up deliberately to attract back Chinese talent that had worked overseas) or to 
work in universities and public research institutions (People’s Daily 2011). The 
Chinese government launched the ‘Thousand Talents’ programme in 2008, and 
attracting returnees is still a high priority for the top leadership (Royal Society 
2011). From the perspective of ‘direction’, however, it can be argued that the 
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skills and specialisms that are brought over to China from abroad focus, again, on 
the treatment of diseases that are most prevalent in wealthier markets overseas. 
Public health benefits as a result of preventative approaches are a direction that 
the returnee trend is unlikely to enhance.
4.2 Distribution – Geographical and between Social Groups
The second ‘D’ highlighted in the New Manifesto (STEPS Centre 2010) concerns 
the equitable distribution of benefits, costs and risks associated with new 
innovations. We have already discussed the distribution of healthcare and health 
equity across China, however there is no data available (to our knowledge) that 
allows us to ascertain the distribution of impacts from China’s innovation activities. 
Instead, we use some of the data available to investigate the distribution of 
different parts of the health biotechnology innovation system across the country as 
a way of understanding the country’s approach to fostering equitable distribution 
of benefits from biotechnology innovation. 
In political documents, the focus is clear. The 12th Five Year Plan for Science and 
Technology (MoST 2011) includes a section devoted to strengthening technology 
for the people’s livelihoods, in which it focuses the first part on accelerating the 
development of health technology, and enhancing the capacity of national health 
protection. A number of traditionally marginalized groups (women, children, 
the elderly and the disabled) are highlighted in particular, as is a focus on the 
prevention of common diseases and appropriate technologies for healthcare in 
rural areas (MoST 2011). But beyond the rhetoric, to what extent is the innovation 
system configured in a way that is likely to serve these innovation goals?
As discussed above, linkages between research institutions, firms, finance and 
markets are all key to effective biotechnology innovation systems. In investigating 
whether China is likely to generate more equitably-distributed health innovations 
than those seen in the West, it is therefore worth looking at current patterns of 
innovative activity (imperfectly recorded through patent-metrics) across different 
parts of the country. Since 2000, the number of all the biotechnology inventions 
patents applications filed in China increased from more than 414 applications in 
2000 to 2482 in 2007. Empirical evidence shows that innovative activities are not 
distributed evenly across the country, with Eastern China being highly innovative 
while other areas demonstrate comparatively less patenting activities (see Figure 
4). 
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Figure 4. Number of Inventions Patents Owned by Pharmaceuticals  Firms in 
China (1995-2007), source: China Statistics Yearbook on High Technology 
Industry (2001-2008).
In the Yangtze River delta, Shanghai, Jiangsu and Zhejiang contributed to 20.3% 
of all medicine invention patents for the 1995-2007 period: Shanghai (4.62%), 
Jiangsu (9.64%) and Zhejiang (6.02%). In China, these three regions accounted 
for nearly 34.75% of all medicine invention patents in biotechnology according to 
the Chinese statistics on high-technology (MoST 2008). According to the Chinese 
Patent document retrieval system (http://www.patent.com.cn), the top five 
geographic regions by number of applications - Beijing, Shanghai, Guangdong, 
Jiangsu and Zhejiang - account for around 60% of all the Chinese biotechnology 
applications by all types and respective categories (see Table 5)
Location Biotechnology 
Applications 
in General
Biotechnology 
Pharmaceutical 
Applications 
Biotechnology 
Fermentation 
Applications
Biotechnology 
Diagnosis 
Applications
Beijing 3543 949 425 1130
Shanghai 2903 792 496 1204
Guangdong 1938 464 207 544
Jiangsu 1792 321 297 644
Zhejiang 1162 213 239 417
Top five 
regions 
(Total 
applications)
59.7% 60% 56.7% 63%
Table 5. Geographic Distribution of Patent Applications in Biotech in China (2003-
2007), source: SIPO, Chinese Patent Document Retrieval System. From: http://
www.patent.com.cn
 4 
screening of compound libraries based on combinatory 
chemistry 
Gene manipulation and 
protein engineering 
Chromosome structure and site-directed integration; design and 
manipulation of protein-coding genes; polypeptide chain 
modification; structure solving; scaled protein purification 
Stem cell-based human 
tissue engineering 
Therapeutic cloning, directional differentiation; in vitro 
construction of structural organs and production; construction 
and damage repair of complex organs with multiple cell types 
New generational industrial 
biotechnology 
Scaled screening of functional microbes; modification of bio-
catalysts and industrial production; bio-conversion media and 
systems for industrial operation 
 
Table 4. Strategic areas of biotechnology specified by the Medium- and Long-term Science and Technology 
Development Plan (compiled from Yu 2007b, taken from Zhang et al. 2010) 
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Applications  
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Applications 
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Shanghai 2903 792 496 1204 
25
Note: With regard to biotechnology patent typology, the main International 
Patent Classification (IPC) classes selected from SIPO databases were A61K 
(pharmaceuticals), C12N, C07K (microbiology, gene and enzyme), C12Q, 
G01N33 (biotech diagnosis), C12P (biotechnology fermentation), C10G3, C12P7 
(biotech energy), (MoST 2008).
As well as ownership being distributed unevenly across the country, there is a 
changing balance between domestic application and foreign applications. Between 
2002 and 2007, domestic inventions patent applications grew rapidly, while 
foreign inventions patent applications showed a more stable pattern (see Table 6), 
suggesting that relative control over the technology was moving slowly towards 
domestic firms. Within the international patent category IPC A61 (biotechnology), 
one of the most important sub-categories (A61K - pharmaceuticals) showed a 
high concentration of patenting activity for both domestic and foreign patents 
applications.
Year In total
2003 2004 2005 2006 2007
Total 
Application
5642 5885 6988 7951 8707 35173
Domestic 
Application
3287 3353 4285 4826 5502 21253
Foreign 
Application
2355 2532 2703 3025 3205 13920
Patents 
granted 
2280 1897 1685 2676 3213 11751
Among them: Biotechnology Pharmaceutical (A61K)
Domestic 
Application
865 863 1110 1091 1663 5592
Foreign 
Application
943 1008 1028 376 675 4030
Patents 
granted to 
Domestic
390 339 311 277 418 1735
Patents 
granted to 
Foreigners
157 49 38 19 29 292
Table 6. Foreign and Domestic Biotech Patent Applications in China (2003-2007), 
source: SIPO, Chinese Patent Document Retrieval System. From: http://www.
patent.com.cn
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Note: Biotechnology patents were categorized by International Patent 
Classification (IPC) classes selected from SIPO databases. ‘Total Application’ 
refers to all main classes of IPC: A61K (pharmaceuticals), C12N, C07K 
(microbiology, gene and enzyme), C12Q, G01N33 (biotech diagnosis); C12P 
(biotechnology fermentation); C10G3, C12P7 (biotech energy). In this analysis, 
we compare this total with the category of pharmaceuticals, i.e. the category of 
A61K from the IPC of SIPO database. 
We have looked at the geographical location of investments and ownership 
as an indicator of whether innovation is taking place in China’s poorer areas, 
however distribution is not just a geographical matter – huge inequalities exist 
between social groups within China’s diverse society and urban/rural differences 
are acute. Market demand for biotechnology products is currently weak in China, 
where more than 35% of urban households and 43% of rural households are 
struggling to afford health care. Exacerbating this situation are remaining 
inefficiencies in the health system. It is estimated that most hospitals derive 40-
60% of their revenue from prescription sales, hospitals remain the main outlets 
for distributing pharmaceuticals in China (CCID Consulting 2009). Distribution 
channels in the rural and marginal regions are dispersed and small-scale, making 
it more challenging for small-scale Chinese domestic biotech firms to reach this 
huge market. At the same time, current arrangements for the new health system 
reforms do not improve the situation. Within the insurance schemes described 
above, different provinces have their own essential drugs lists, but more expensive 
(patented) biotech drugs are rarely supported. Under the 2009–2011 Action Plan 
on China’s Healthcare Reform (which aimed to extend free primary healthcare 
to rural areas), the government announced its intention to develop a national 
list of essential drugs that would be produced and distributed under government 
control and supervision and would be available at all public health facilities and 
retail drugstores from 2009 (The Central People’s Government 2010). It is unclear 
whether this national list could be used as a tool for driving Chinese innovations 
serving poorer markets, or even serve as a tool for future problems that are 
likely to emerge in China before other parts of the world (e.g. through the use 
of advance-market commitments, discussed below). One such problem is that 
of antibiotic resistance amongst micro-organisms causing infectious diseases. 
Clearly, as discussed in Box 2 below, market signals have been insufficient to 
incentivize private sector R&D in this field over recent decades. In partnership with 
the international community, China has a role to play in incentivizing innovation in 
this area in order to avert a possible impending public health catastrophe.
Box 2. Case Study – Innovation for combating antimicrobial resistance in China
Widespread use and misuse exists worldwide, and increasing rates of microbial 
resistance to antibiotics have become a major public health problem, not only in 
low and middle income countries, but also in high income countries (Cars et al. 
2008). Globally, only two new classes of antibiotics have been developed in the 
past 30 years, and research and development into new antibiotics is decreasing 
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(Infectious Diseases Society of America 2004).
Antibiotics are the most commonly prescribed medicine in China, accounting for 
30–50% of all drug consumption (Xiao et al. 2008). Work by Zhang et al. (2006) 
indicates that China has more severe antimicrobial resistance and more rapid 
spread of antimicrobial resistance (22% average growth in a study spanning 
1994 to 2000) than both Kuwait and the United States. Based on the surveillance 
results from 17 tertiary hospitals located in 15 cities in China, Xiao et al. (2008) 
concluded that antibacterial resistance in China is more serious than North 
America and Europe, for example stating that about 65% of the Escherichia coli 
strains were resistant to fluoroquinolones in 2004–2005. 
Historically, antibiotics were freely available through barefoot doctors (Zhang and 
Unschuld 2008) or over the counter at public and private health facilities, until 
a notice was issued by the State Food and Drug Administration (SFDA) on 1 
July 2004 which ordered that antibiotics should not be sold without prescription. 
Studies have shown that over-the-counter sales of antibiotics continue, and that 
operating under perverse incentives, private clinics still often provide unnecessary 
and expensive antibiotics in order to maximise profits within the privatised health 
system. These patterns of overuse threaten to increase medical costs and 
accelerate antibiotic resistance, whilst raising the risk of hospital infection with 
resistant strains and potentially undermining the very drugs on which so much 
modern medicine relies. 
Research in rural Hubei and Shandong (Jin et al. 2011) suggests that Chinese 
citizens expect the government to take care of problems of antibiotic resistance. 
Whilst promoting (and enforcing) rational use of antibiotics is obviously an 
urgent and vital step in this regard, the need for international investment in a 
new generation of these drugs is also clear. China’s growing biotechnology 
capabilities and large population (over-) relying on antibiotics, suggests that the 
country should take a more proactive role in global innovation efforts to overcome 
the problems of antimicrobial resistance. The application of innovative financing 
mechanisms to provide incentives for firms to invest in this area are a possible 
area for future research and policy discussion.
4.3 Diversity – TCM and public health approaches
China’s unique national history as the world’s oldest continuous civilization, and the 
country’s multiple ecologies have resulted in a great diversity in health conditions 
and responses (Han et al. 2008). China’s research portfolio has historically tended 
to focus efforts within core programmes, driven by national priorities (IDRC/SSTC 
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1997) and, as illustrated by some of the programmes described above, continues 
to current times. Diversity has not been a key consideration in the setting of 
these priorities, however as well as the relatively homogeneous ‘international’ 
directions covered in earlier sections, a considerable amount of diversity exists in 
the Chinese health research system. 
One area that contributes to the diversity of China’s health biotechnology research 
system (and contributes significantly to the diversity of the global health research 
portfolio) is that of traditional Chinese medicine (TCM). China has, more than 
any other ‘developing’ country, used its rich traditional pharmacopoeia in modern 
research programmes. The importance and potential of TCM has been recognized 
since Mao’s time, when the leadership promoted the continued use of TCM, 
for example within the barefoot doctor system. Recent investment in research 
(including a number of universities dedicated to TCM and the application of 
modern biotechnologies to TCM treatments) have tried to take a more integrative 
approach, and the modernization of TCM using biotechnological methods such 
as high-throughput screening provides opportunities for candidate drugs to be 
identified faster, improving the efficiency of product development in Chinese firms 
working in this area (Zhang et al. 2010). The benefits assist not only the Chinese 
population, but have also made significant global impacts.
A number of examples exist, perhaps the most celebrated of which is the use 
of artemisinins to treat Malaria (Pandey et al. 1999). These drugs, developed 
from Artemisia annua (used for centuries in traditional Chinese medicine), are 
now the most common group of drugs used to treat the disease across the 
African continent. However, they are also threatened with resistance problems. 
This prompted worldwide efforts to rationalize use and improve formulations (for 
example through including them in combination therapies) in order to delay the 
obsolescence of these life-saving drugs (Arrow et al. 2004), although artemisinin-
resistant malaria has already been identified in South East Asia. Long-term 
stewardship of medicines is also a challenge faced by China’s dynamic health 
system in respect to antibiotics (discussed below). International interest has led to 
the development of new drugs from TCM knowledge. The Institute of Microbiology 
of the Chinese Academy of Sciences has engaged in strategic alliances with 
international partners to develop new treatments for TB, partnering with the US-
based ‘Global Alliance for TB Drug Development’ (Hille and Jack 2009). 
Some argue that the focus on individual active ingredients detracts from the 
holistic approach that traditionally characterizes true TCM1, which is based on 
a deep philosophical notion of balance (Tang, J. et al. 2008) and which is lost 
when doctor-patient interaction is reduced to prescription (or more often rendered 
obsolete through the availability of OTC drugs). Nevertheless formulations of 
1 Interview with scientists from Institute of Traditional Chinese Medicine, Guangdong 
Pharmaceutical University, 4th August 2007.
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raw materials (e.g. powdered plant material encased in capsule form), as well 
as pills containing isolated or synthesized active ingredients are common within 
different sectors of China’s health system. In 2006, the TCM sector provided 
care for over 200 million outpatients and some 7 million inpatients, accounting 
for 10% - 20% of health care in China (GOSATCM 2006 cited in Tang, J. et al. 
2008). Challenges to technological upgrading in the development of traditional 
medical knowledge and integration within the Chinese biotechnology industry 
also include the difficulties involved with trials for efficacy and side-effects (Tang, 
J. et al. 2008) and ongoing reforms in product regulation (especially with regard 
to internationally harmonized pharmaceutical standards). However, despite these 
challenges, MNE representatives have stated that they are ‘just one step away 
from TCM-based products being launched on the global market’ (Wilsdon and 
Keeley 2007).
Beyond the focus on high-tech, product and service innovation, China has also 
pioneered a number of social and organizational innovations in its health system. 
Reformulating incentive structures, creating new institutions and introducing new 
financial arrangements have taken place possibly because of the activities of 
different stakeholders in the co-construction of an effective health system (Bloom 
2011). At the same time, infrastructural development, for example through the 
development of an online disease surveillance system (Han et al. 2008) has 
played an important role. Community health-workers that were refashioned as 
‘barefoot doctors’ in rural China (Zhang and Unschuld 2008) have been used as a 
model for taking healthcare to the poor in other countries. The focus on capacity-
building in rural settings is not so great within the new systems of healthcare 
being developed in China, and training local doctors remains a challenge (Zhang 
and Unschuld 2008). 
At the same time, China has been slower to invest in public participation in the 
health system (e.g. through public health education). Although the government 
does support educational programmes/ propaganda on state-television and 
radio, low levels of public understanding are recognized as a challenge. Disease 
prevention through infant immunization was also somewhat neglected during 
the 1990s (Liu et al. 2008). This kind of preventative healthcare, which does not 
produce such direct impacts on GDP as sales of curative therapies, has been 
highlighted as lacking by scholars evaluating China’s health system (Liu et al. 
2008). 
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5. Opportunities for enhancing ‘3D’ 
health innovation in China
In drawing upon the preceding discussions and considering the future 
opportunities for enhancing ‘3D’ health innovation in China, this section is divided 
into three parts. The first part analyses the situation in China and discusses how 
its contribution to a ‘3D’ agenda for social sustainability might be enhanced. The 
second looks at the international context and discusses governance changes at 
the global level which may also help these domestic changes. The final section 
points towards innovation studies research that has analysed government and 
non-government approaches to enhancing pro-poor innovation, and suggests 
possible future research options around similar questions in China. 
5.1 Enhanced participation and Market Creation 
for Biotechnology Innovation in China
Leach and Scoones (2006) have argued that ‘innovation should not only focus 
on technology itself, but also on the social, cultural and institutional relationships 
that will enable the technology to work.’ To make existing technologies accessible 
to people living under the poverty line thus requires both technical and social 
interventions. ‘To enable poor people to make use of technologies that may 
be available, but are poorly understood, often requires culturally appropriate 
communication strategies, improving people’s knowledge and power to make 
technology choices’ (Leach and Scoones 2006). When considering national 
innovation systems, it’s vital to extend the ‘hardware’ of R&D infrastructure 
and capabilities to the social and political relations among many actors, and 
the different interests that shape science and technology (Leach and Scoones 
2006). As illustrated by the earlier discussion of governing innovation for 
sustainability, providing these different ‘interests’ with opportunities for an ongoing 
dialogue around sustainability goals and objectives forms part of the ‘process’ 
of sustainable development. Government-funded research, and the increasing 
dominance of the private sector in innovation may prevent technology from 
following pro-poor directions, while the involvement of a broader set of actors 
in the innovation system (including in the setting of research priorities and 
engagement in product development and commercialisation) may help to open 
up possibilities for alternative pathways (Stirling et al. 2007). More networked and 
inclusive forms of technology assessment can help to build capabilities throughout 
innovation systems and promote understanding of these different pathways (Ely 
et al. 2011). Civil society can also play a significant role in governance at national 
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and international levels. International organizations, scientific experts, and non-
governmental organizations (NGOs) can add critical and alternative voices 
(Scholte 2007). Emerging arrangements such as public-private partnerships 
(PPP), publicly-funded initiatives and private technology entrepreneurship in poor 
regions, as well as innovative approaches to ‘inclusive regulation’, for example 
around intellectual property, are advocated by Leach and Scoones (2006). 
Increased access to information is opening up opportunities for citizen engagement 
around science and technology in China, whether through the formal media or 
through online discussions. Developing countries, like China and India, are facing 
challenges for building civic infrastructure and citizen engagement. They have 
different incentives and barriers, often suffering from a lack of a viable institutional 
framework, civic infrastructure, cultural differences, time pressures and poverty 
(Denhardt et al. 2009). Whilst China’s traditional governance mode does not lend 
itself to broader participation in decision-making around directions of research 
and innovation, gradual political reform offers the possibility for stakeholder and 
citizen engagement – for example through technology assessment activities 
- to contribute to a ‘3D’ agenda. Facilitating networks around biotechnology 
development and deployment is one way that the government can help to 
establish contacts and linkages between different stakeholders working in the 
field. Examples from elsewhere, such as the Indian-led Open Source Drug 
Discovery initiative (OSDD), have drawn upon public-private collaboration and 
the voluntary contributions of students and researchers to deliver remarkable 
results in the search for TB drugs (Massum et al. 2011), a challenge that could 
also benefit many of China’s rural areas. Similar experiments in China have not, 
to date, been explored. 
Citizen engagement can enable poorer sections of society to articulate their 
needs more strongly than traditional market signals allow them to do so. At the 
same time, however, there are many ways in which facilitating inclusion in markets 
and supporting the institutions around them can help to improve health services 
(Bloom et al. 2009). Expanding domestic biotech product demand is an imperative 
for the Chinese Government (not only in health but throughout the economy). 
Strengthening health systems infrastructure and distribution mechanisms can 
form the basis for part of this demand, whilst at the same time responding to 
the urgent challenges around health equity described above. Government should 
increase support to clinicians and facilities in rural or isolated regions, and scarce-
resource urban regions. As Liu et al.’s (2006) study on health care in China 
shows, the private sector or non-government providers tend to serve the low-
middle income class in China, with relatively lower costs and higher consumer 
satisfaction. This is another channel of reaching potential consumers and expands 
the biotech product demand. However, this non-government solution tends to be 
self-organizing, and requires timely regulation – another reason to involve these 
kinds of stakeholders in governance processes. 
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Analysis of pro-poor health innovation initiatives involving the biotechnology 
industry in the West (only mentioning China’s role in terms of CRO involvement) 
points to the challenges of translating promising research on neglected diseases 
in the lab to impactful innovations in the field (BVGH 2007). As discussed above, 
although research in fields of relevance to China’s poorer populations is ongoing, 
institutional mechanisms are not necessarily in place to ensure that they will be 
commercialized. Market-pull incentives are urgently required. 
A fundamental restructuring of the payment system, reducing the high out-of-
pocket payments and expanding broad insurance coverage is already underway 
(Hu et al. 2008) and is of great significance to China’s Biotech product demand. 
The opportunities for co-ordinating across different areas of China (e.g. through 
a national essential medicines list), thus linking this huge demand at the bottom 
of the pyramid (Prahalad 2004) to the biotechnology innovation system presents 
possibilities for supporting not only indigenous but also pro-poor innovation. 
Subsequent improvements in health amongst rural populations over the longer 
term could increase their capabilities to contribute to the country’s development 
in an ongoing, virtuous cycle. Similarly, as discussed above in the case study of 
antibiotics, market signals need to be created to drive innovation that responds 
to future health needs. The possibility of extending the use of essential medicine 
lists to act as a tool for incentivizing innovation (for example in conjunction with 
advance market commitments) needs to be investigated.
5.2 Global Governance to Enhance Biotech 
Innovation Systems in Developing Countries
Global science and technology governance is complicated by severe coordination 
problems. Within a liberal multilateral trading system, these arise as nations 
compete to seize the perceived ‘first mover’ advantage and to encourage firms 
to locate within their borders. This leads to ‘hyper-competition’ which wastes 
money, human resources and other resources and create systemic friction (Stone 
2008). Problems of co-ordination can also contribute to threats of neo-techno-
nationalism, orphan public goods, and nationalistic backlashes to the accelerating 
emergence of global innovation networks (Ernst and Hart 2008). In the area 
covered by this paper, as with global innovation governance more generally, a 
more co-operative approach involving international collaboration networks needs 
to be enhanced (Chen et al. 2011), and institutional innovations are required in 
order to promote and co-ordinate research and innovation for global public goods. 
The STEPS Centre’s New Manifesto proposes an international body - a ‘global 
innovation commission’ - which could contribute to these requirements.
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At the same time, existing institutions are in need of reform in instances where 
they discourage innovation for social sustainability goals in developing countries. 
The global biotech industry is governed to a significant extent by the Agreement 
on Trade-Related Intellectual Property Rights (TRIPS) under the World Trade 
Organization (WTO). Current intellectual property arrangements are not conducive 
to promoting innovation in pro-poor technologies or enhancing access to these 
technologies in developing countries (Abdelgafar 2001; WHO 2001). After China 
entered the WTO in 2001, it adjusted its IP regulations to comply with the TRIPS 
agreement. As a result of the TRIPS regime, the need to maintain multiple patents 
across various countries is extremely expensive and emerging biotech firms from 
countries such as China struggle to access the market even in the domestic 
setting. Some transnational companies even set ‘patent traps’, taking advantage 
of their dominant international patents in developing countries like China (Frew et 
al. 2008). This creates enormous challenges for Chinese biotech firms both in the 
international and domestic market.
The third amendment to China’s patent law already made some innovative 
changes that went beyond the scope of TRIPS, for example requiring the 
reporting of providence when a patent relies on the use of genetic resources 
(Zhu et al. 2008). In addition, the latest amendment allows compulsory licenses 
for drugs protected under Chinese patents on the basis of a ‘national emergency 
or any extraordinary state of affairs … or where the public non-commercial use 
so requires’ (following the Doha Declaration) or on the basis of public health, 
for export to the least developed countries or countries that have insufficient 
capacity for the manufacture of the drug. Whilst it should not be used as a tool 
for unfairly supporting domestic biotechnology firms, this clause could in theory 
serve health equity concerns either in China or elsewhere. Under conditions of 
increasing antimicrobial resistance, for example, the need to prevent increasing 
healthcare costs might necessitate the compulsory licensing of more expensive, 
patented antibiotics not usually affordable to China’s poorer patients. The current 
patent regime creates a number of conflicting pressures, in some cases both 
incentivising irrational use (in order to maximize profits whilst patents are in 
force) and disincentivising investment in new drugs (when IP protection or license 
payments are in question). In this particular case, there is an urgent need for 
international co-ordination, beyond the current activities of the WHO to include 
intellectual property reform and institutions to foster innovation towards this global 
public good.
There are crucial challenges to fostering public health and supplying basic 
treatments for diseases prevalent  in developing countries, but these fail to 
receive the resources and support that their nations urgently need (Xue 2008). 
For instance, only 11 out of 1,223 new pharmaceuticals developed between 1975-
1996 were for the treatment of tropical diseases, according to WHO. This is partly 
due to perverse incentive mechanisms and partly due to the weak capability in 
developing countries themselves. The current global governance framework also 
hampers the development of biotech companies in developing countries, which 
34
are perhaps best-placed to respond to challenges faced by their populations. From 
a Chinese perspective, the continued dominance of multinational firms hampers 
efforts to provide affordable healthcare to the country’s poor. More accountability 
and responsibility of the transnational biotech firms around providing access 
to basic biotech products, should be encouraged (Greve 2008) and firms that 
contribute proactively, for example by opening up research databases (Nature 
2010) should be rewarded. Regulatory frameworks and the role of international 
institutions, particular the TRIPS agreement are also a key concern (Juma et 
al. 2001). Finding ways of balancing the cooperation between developed and 
developing countries, whilst assuring that the  incentives for innovation are not 
undermined is key, and more research is required to understand how health 
equity can be promoted by global governance frameworks (Pogge 2005). 
5.3 Conclusions and Future Research Possibilities
This paper identifies the opportunities and challenges of China’s health 
biotechnology innovation system for social sustainability in China and beyond. 
R&D capabilities have improved significantly in China over the past decades, but 
with a concentration in leading universities and research institutions, and alongside 
insufficient collaborations and linkages between different players in the National 
Innovation System. Further investigation is required to better understand how pro-
poor research generated in laboratories can best be translated to the market, given 
insufficient demand-pull incentives in many cases. Government procurement of 
innovative products from domestic biotech firms for the benefit of poorer patients, 
strengthening health system infrastructure and distribution channels to ensure 
the availability of innovative health-biotech products to the poorer patients, and 
working with non-government providers to construct supplementary distribution 
channels, are all relevant to harnessing China’s enormous but untapped market 
and contributing to the growth of the domestic biotech industry. China’s huge 
population presents not only an advantage in the marketing of drugs, but also 
their development and testing (Li et al. 2004). However, this advantage has not 
been leveraged to the full possible extent. The potential for linkages between 
the dynamic health system, currently undergoing radical reforms, and the 
nascent biotechnology sector, remain under-investigated. Lessons from China 
could contribute a great deal to our understanding of biotechnology policies, 
supplementing information from other developing countries around science, 
finance, ethics, society and culture and politics (Daar et al. 2007). Targetted 
case studies may provide a way forward – for example through investigating the 
economics of specific neglected diseases (or problems like antibiotic resistance) 
and the potential financial tools available to promote innovation towards their 
prevention and treatment.
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Biotech innovation in China is still concentrated and depends largely on returnees 
and international firms – primarily in the East of the country. At the same time, 
multi-national firms still dominate, driving the sector towards innovations serving 
wealthy overseas or domestic markets and maintaining a hold over intellectual 
property. More research is required to document the innovation focus of domestic 
and international firms from different parts of the country, and to look into 
mechanisms for enhancing the more equitable distribution of resources to parts 
of China’s innovation system that are currently lagging but are well-placed to 
serve marginalized communities. The diversity of China’s investment in various 
health paradigms (including in traditional Chinese medicine) could be better-
understood by analysis using measures of disparity and diversity metrics (Stirling 
2007). Civil society groups do not currently participate in knowledge creation, 
technology development or policy-making for biotech research, which are largely 
driven by government and elite scientists. While opportunities for including such 
groups in decision-making are limited, more participatory forms of technology 
assessment might provide interesting insights to the kinds of contributions that 
non-governmental actors could make. New models of international science 
collaboration are required, but with a renewed focus on co-ordination across 
countries and firms to enhance the production and sharing of global public 
goods knowledge. As China becomes an ever more important player on the 
global innovation scene, collaborative social science research is also important 
to inform policies at national and international levels, and foster understanding 
across national borders. Readjusting the global governance regime, balancing 
the impacts of IPR regulation between developed and developing countries and 
making timely adjustments to domestic regulations, are of vital importance for 
the social sustainability impacts of biotech innovation in developing countries like 
China, and more globally. 
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